| Identification | Back Directory | [Name]
13,14-dihydro-15-keto-tetranor Prostaglandin E2 | [CAS]
20675-85-8 | [Synonyms]
13,14-dihydro-15-keto-tetranor Prostaglandin E2
13,14-dihydro-15-keto-tetranor Prostaglandin E2 Exclusive
Cyclopentanepropanoic acid, 3-hydroxy-5-oxo-2-(3-oxooctyl)-, [1R-(1α,2β,3α)]- (9CI) | [Molecular Formula]
C16H26O5 | [MDL Number]
MFCD18428006 | [MOL File]
20675-85-8.mol | [Molecular Weight]
298.37 |
| Hazard Information | Back Directory | [Description]
A common metabolic pathway for several prostaglandins (PG), including PGE2, involves the reduction of the double bond between C-13 and C-14 and oxidation of the hydroxyl group at C-15, producing 13,14-dihydro-15-keto PGs. The removal of four carbons at the α-terminus and oxidation of the terminal ω-carbon produces the abundant urinary metabolites, including tetranor PGEM.1 13,14-dihydro-15-keto-tetranor PGE2 is a potential metabolite of PGE2. It would be produced from the known metabolite 13,14-dihydro-15-keto PGE2 , which is known to have a short plasma half-life.2,3,4 | [References]
1. Hamberg, M. Inhibition of prostaglandin synthesis in man Biochem. Biophys. Res. Commun. 49(3),720-726(1972).
2. Bothwell, W., Verburg, M., Wynalda, M., et al. A radioimmunoassay for the unstable pulmonary metabolites of prostaglandin E1 and E2: An indirect index of their in vivo disposition and pharmacokinetics J. Pharmacol. Exp. Ther. 220(2),229-235(1982).
3. Fitzpatrick, F.A., Aguirre, R., Pike, J.E., et al. The stability of 13,14-dihydro-15 keto-PGE2 Prostaglandins 19(6),917-931(1980).
4. Granstr?m, E., Hamberg, M., Hansson, G., et al. Chemical instability of 15-keto-13,14-dihydro-PGE2: The reason for low assay reliability Prostaglandins 19(6),933-945(1980). |
|
|